Navigation Links
Radiologists study necessity of additional imaging recommendations in PET/CT oncologic reports
Date:5/3/2012

Advanced imaging has been identified as one factor that contributes to the overall rising cost of healthcare in the US. Unnecessary or inappropriate imaging utilization magnifies the cost burden associated with advanced imaging studies like MRIs and PET/CT scans. Though these studies often provide the best clinical information for making a diagnosis or planning treatment, experts suspect that a significant number of unnecessary studies are performed. Determining the rate of unnecessary imaging can help guide both policy-makers and physicians to develop guidelines that would ultimately reduce costs associated with advanced medical imaging.

A recent study by researchers from Brigham and Women's Hospital Department of Radiology adds new data about unnecessary imaging among cancer patients. Atul Shinagare, MD and attending radiologist, Paul B. Shyn, MD reviewed the reports attached to the PET/CT scans of 250 cancer patients and found that 84 of the reports contained a nuclear medicine physician or radiologist's recommendation for additional imaging tests. Further analysis led the researchers to conclude that 43 (approximately half) of those recommendations were unnecessary.

"Our research indicates that imaging specialists can substantially reduce the frequency of recommendations for additional imaging tests in oncologic PET/CT reports without adversely impacting patient outcomes," said Dr. Shinagare.

Other key findings from the study, which will be presented at the American Roentgen Ray Society Annual Meeting, May 4th in Vancouver, Canada, include:

  • Eighty-four, or approximately 30 percent of the total number of PET/CT reports contained a recommendation for additional imaging.
  • Additionally, referring physician did not follow through on 70 percent of the recommendations for additional imaging.

The study's protocols did not call for the authors to specifically investigate the reader motivations behind the additio
'/>"/>

Contact: Bryan Murphy
bmurphy9@partners.org
617-732-7088
Brigham and Women's Hospital
Source:Eurekalert

Page: 1 2

Related biology news :

1. Interventional radiologists see significant symptom relief in MS patients
2. Interventional radiologists: Learn about peripheral arterial disease and get moving
3. Interventional radiologists provide hope in delaying growth, spread of breast cancer
4. Interventional radiologists advance MS research: Vein-opening treatment safe
5. Interventional radiologists take lead on reducing disability from dangerous blood clots
6. Radiologists play key role in teaching physiology to medical students
7. Top interventional radiologists, neurointerventionists explore stroke care through CLOTS
8. Plant diversity is key to maintaining productive vegetation, U of M study shows
9. Study discovers genetic pathway impacting the spread of cancer cells
10. TGen leads new National Institutes of Health study of brain tumors
11. First-of-its-kind study reveals surprising ecological effects of earthquake and tsunami
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... DNA and this modification can occur in millions ... scientists believed that this epigenetic phenomenon actively reduced ... of researchers from the University of Geneva (UNIGE), ... the Faculty of Medicine, reveals that this is ... may play both a passive and active role ...
(Date:6/17/2013)... in patients with severe brain infections in Vietnam. Further ... responsible for the symptoms of disease. , The virus ... 644 patients with severe brain infections in the study, ... the 122 patients with non-infectious brain disorders that were ... system are often fatal and patients who do survive, ...
(Date:6/17/2013)... improving original foundations with more modern elements. Using this ... Kenneth P. Dietrich School of Arts and Sciences have ... delivery, gas storage, and gas transport more efficient and ... the latest issue of the Journal of the ... recent work builds upon Pitt Associate Professor of Chemistry ...
Breaking Biology News(10 mins):The secret of DNA methylation 2New virus isolated from patients with severe brain infections 2New virus isolated from patients with severe brain infections 3'Chemical architects' build materials with potential applications in drug delivery and gas storage 2
... relatedness of an animal food protein to a human protein ... by scientists from the Institute of Food Research in Norwich ... proteins have the potential to become allergens, but the study ... to act as allergens depends on their evolutionary distance from ...
... pathway that plays a critical role in the growth ... important insight into the development of the vascular system ... inhibiting the blood vessels that fuel cancers, diabetic eye ... published online on Oct. 14 in Nature Genetics. was ...
... 2007Today at the Prostate Cancer Foundations Annual Scientific Retreat, ... foods such as tomatoes and fish, maintaining a healthy ... help prevent prostate cancer, and help men live healthier ... will be diagnosed with prostate cancer in their lifetime, ...
Cached Biology News:Animal food allergens unmasked 2Study reveals a key to blood vessel growth and possible drug target 2Study reveals a key to blood vessel growth and possible drug target 3Leading researchers to reveal comprehensive dos and don'ts for prostate cancer 2Leading researchers to reveal comprehensive dos and don'ts for prostate cancer 3
(Date:6/18/2013)... -- RegeneCure announced today the start ... Bone Regeneration (GBR) Dental Membrane as a bone stimulating aid ... encountered when patients have a tooth replaced with a dental ... the implant. Consequently there is often a need to support ... regenerates. The bone substitute material, in turn, needs to be ...
(Date:6/18/2013)... June 18, 2013 The "Bioinformatics Market By ... Knowledge Management Tools & Data Analysis Services) & Application (Genomics, ... the Major Market Drivers, Restraints, and Opportunities in ... Asia-Pacific and Rest of World. ... 22 Figures 364 ...
(Date:6/18/2013)... , June 18, 2013 ... ) has announced the addition of the ... [Liposomes, Microspheres, & Nanoparticles], Devices [Disposables & ... & Auto Injectors] & Therapeutics [Diabetes & ... report to their offering.      ...
(Date:6/18/2013)... Inflamax Research Inc., a full ... Phase I-IV clinical trials, announced today that they ... Environmental Technologies (NAET), a specialty air conditioning & ... servicing of mobile Environmental Exposure Chambers (EECs) used ... , Inflamax Research has proprietary Next ...
Breaking Biology Technology:RegeneCure Starts Clinical Study Using Polymeric Bone Stimulating Membrane for Dental Implants 2RegeneCure Starts Clinical Study Using Polymeric Bone Stimulating Membrane for Dental Implants 3Bioinformatics Market Worth $7.5 Billion by 2017 2Bioinformatics Market Worth $7.5 Billion by 2017 3Injectable Drug Delivery Market by Formulations, Devices & Therapeutics - Global Forecasts to 2017 2Injectable Drug Delivery Market by Formulations, Devices & Therapeutics - Global Forecasts to 2017 3Inflamax Research Inc. Enters Strategic Partnership with Northern Air Environmental Technologies Inc. 2Inflamax Research Inc. Enters Strategic Partnership with Northern Air Environmental Technologies Inc. 3
... Eastern Time -, SAN FRANCISCO, Nov. 10 ... corporate progress and financial,results for the quarter ended September ... of significant,achievement and progress and was capped with the ... collaboration not only gives us,access to a world-class partner ...
... Conference Call Today To Discuss the Data and Ongoing ... Clinical Development Programs, ... announced today top-line data from its,SB-509-601 clinical trial, one of Sangamo,s ... SB-509 for diabetic,neuropathy (DN). The data demonstrate that repeat administration of ...
... Divestitures of Non-Core Product Lines -, HOPKINTON, ... CALP ) today reported third quarter financial,results ... line divestitures: the,sale of its AutoTrace(R) product line ... of its Pharmaceutical Development and Quality Analysis,(PDQ) product ...
Cached Biology Technology:Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update 2Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update 3Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update 4Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update 5Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update 6Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update 7Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update 8Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601 2Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601 3Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601 4Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601 5Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601 6Caliper Life Sciences Reports Third Quarter 2008 Results; Sharpens Growth Focus, Strengthens Balance Sheet and Reduces Costs 2Caliper Life Sciences Reports Third Quarter 2008 Results; Sharpens Growth Focus, Strengthens Balance Sheet and Reduces Costs 3Caliper Life Sciences Reports Third Quarter 2008 Results; Sharpens Growth Focus, Strengthens Balance Sheet and Reduces Costs 4Caliper Life Sciences Reports Third Quarter 2008 Results; Sharpens Growth Focus, Strengthens Balance Sheet and Reduces Costs 5Caliper Life Sciences Reports Third Quarter 2008 Results; Sharpens Growth Focus, Strengthens Balance Sheet and Reduces Costs 6Caliper Life Sciences Reports Third Quarter 2008 Results; Sharpens Growth Focus, Strengthens Balance Sheet and Reduces Costs 7Caliper Life Sciences Reports Third Quarter 2008 Results; Sharpens Growth Focus, Strengthens Balance Sheet and Reduces Costs 8Caliper Life Sciences Reports Third Quarter 2008 Results; Sharpens Growth Focus, Strengthens Balance Sheet and Reduces Costs 9Caliper Life Sciences Reports Third Quarter 2008 Results; Sharpens Growth Focus, Strengthens Balance Sheet and Reduces Costs 10Caliper Life Sciences Reports Third Quarter 2008 Results; Sharpens Growth Focus, Strengthens Balance Sheet and Reduces Costs 11
Blue Standard is 3-cyano-7-hydroxycoumarin....
Cyan Standard is 7-hydroxy-4-trifluoromethylcoumarin...
6-(2,4-dinitrophenyl)aminohexanoic acid, succinimidyl ester (DNP-X, SE)...
Endothelin-converting enzyme 1 (EC 3.4.24.71) (ECE-1). [Source:Uniprot/SWISSPROT;Acc:P42892] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Biology Products: